Haloperidol Plasma Levels and Clinical Response in Paranoid Schizophrenics

Overview

Journal Eur Arch Psychiatry Neurol Sci

Specialties Neurology
Psychiatry

Date 1984 Jan 1

PMID 6526061

Citations 4

Authors

P Linkowski

P Hubain

R von Frenckell

J Mendlewicz

Affiliations

Soon will be listed here.

Abstract

The relationship between haloperidol plasma levels, plasma prolactin, and therapeutic efficacy was evaluated in 20 paranoïd schizophrenics in a fixed-dose study for 6 weeks. We found a significant intrapatient cross-correlation of therapeutic efficacy, as measured by decrease in MSS and BPRS rating scales and time-dependent haloperidol and prolactin changes, which were tested at weekly intervals. However, no significant curvilinear relationship was present between steady-state haloperidol plasma levels and MSS and BPRS improvement scores. Our data do not furnish clear-cut evidence in favor of the existence of a therapeutic window for haloperidol plasma levels in paranoïd schizophrenia.

Citing Articles

Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Miller R Curr Neuropharmacol. 2010; 7(4):315-30.

PMID: 20514211 PMC: 2811865. DOI: 10.2174/157015909790031184.

The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.

Ulrich S, Wurthmann C, Brosz M, Meyer F Clin Pharmacokinet. 1998; 34(3):227-63.

PMID: 9533984 DOI: 10.2165/00003088-199834030-00005.

Plasma level monitoring of antipsychotic drugs. Clinical utility.

Dahl S Clin Pharmacokinet. 1986; 11(1):36-61.

PMID: 2868820 DOI: 10.2165/00003088-198611010-00003.

Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia.

Kelly M, Perry P, Coryell W, Miller D, Arndt S Psychopharmacology (Berl). 1990; 102(4):514-20.

PMID: 2096408 DOI: 10.1007/BF02247134.

References

Kucharski L, Alexander P, TUNE L, Coyle J . Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients. Psychopharmacology (Berl). 1984; 82(3):194-8. DOI: 10.1007/BF00427772. View

Spitzer R, Endicott J, Robins E . Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978; 35(6):773-82. DOI: 10.1001/archpsyc.1978.01770300115013. View

Crow T . Molecular pathology of schizophrenia: more than one disease process?. Br Med J. 1980; 280(6207):66-8. PMC: 1600263. DOI: 10.1136/bmj.280.6207.66. View

Davis J . Recent developments in the drug treatment of schizophrenia. Am J Psychiatry. 1976; 133(2):208-14. DOI: 10.1176/ajp.133.2.208. View

Mavroidis M, Kanter D, Hirschowitz J, Garver D . Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology (Berl). 1983; 81(4):354-6. DOI: 10.1007/BF00427577. View

Bjorndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestrich I . High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology (Berl). 1980; 67(1):17-23. DOI: 10.1007/BF00427590. View

Johnstone E, Crow T, Frith C, Carney M, Price J . Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet. 1978; 1(8069):848-51. DOI: 10.1016/s0140-6736(78)90193-9. View

Meltzer H, Busch D, Fang V . Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res. 1983; 9(4):271-83. DOI: 10.1016/0165-1781(83)90001-x. View

Neborsky R, Janowsky D, Munson E, Depry D . Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Behavioral considerations. Arch Gen Psychiatry. 1981; 38(2):195-9. DOI: 10.1001/archpsyc.1981.01780270081011. View

10.

Rao V, Bishop M, Coppen A . Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. Br J Psychiatry. 1980; 137:518-21. DOI: 10.1192/bjp.137.6.518. View

11.

Angrist B, Rotrosen J, Gershon S . Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology (Berl). 1980; 72(1):17-9. DOI: 10.1007/BF00433802. View

12.

Rimon R, Averbuch I, Rozick P, Kara T, Dasberg H, Ebstein R . Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients. Psychopharmacology (Berl). 1981; 73(2):197-9. DOI: 10.1007/BF00429218. View

13.

Cookson J, Moult P, Wiles D, Besser G . The relationship between prolactin levels and clinical ratings in manic patients treated with oral and intravenous test doses of haloperidol. Psychol Med. 1983; 13(2):279-85. DOI: 10.1017/s0033291700050893. View

14.

GUTTMACHER M . PHENOTHIAZINE TREATMENT IN ACUTE SCHIZOPHRENIA; EFFECTIVENESS: THE NATIONAL INSTITUTE OF MENTAL HEALTH PSYCHOPHARMACOLOGY SERVICE CENTER COLLABORATIVE STUDY GROUP. Arch Gen Psychiatry. 1964; 10:246-61. View

15.

Gruen P, SACHAR E, Langer G, Altman N, Leifer M, Frantz A . Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry. 1978; 35(1):108-16. DOI: 10.1001/archpsyc.1978.01770250110011. View

16.

Reschke R . Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Dis Nerv Syst. 1974; 35(3):112-5. View

17.

Meltzer H, Fang V . The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry. 1976; 33(3):279-86. DOI: 10.1001/archpsyc.1976.01770030003001. View

18.

Magliozzi J, Hollister L, Arnold K, Earle G . Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry. 1981; 138(3):365-7. DOI: 10.1176/ajp.138.3.365. View

19.

Rotrosen J, Angrist B, Gershon S, Aronson M, Gruen P, SACHAR E . Thiethylperazine; clinical antipsychotic efficacy and correlation with potency in predictive systems. Arch Gen Psychiatry. 1978; 35(9):1112-8. DOI: 10.1001/archpsyc.1978.01770330086008. View

20.

Gottschalk L, Biener R, Noble E, Birch H, Wilbert D, Heiser J . Thioridazine plasma levels and clinical response. Compr Psychiatry. 1975; 16(4):323-37. DOI: 10.1016/s0010-440x(75)80002-2. View